BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 16566729)

  • 1. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.
    Verigos K; Stripp DC; Mick R; Zhu TC; Whittington R; Smith D; Dimofte A; Finlay J; Busch TM; Tochner ZA; Malkowicz S; Glatstein E; Hahn SM
    J Environ Pathol Toxicol Oncol; 2006; 25(1-2):373-87. PubMed ID: 16566729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy with motexafin lutetium for rectal cancer: a preclinical model in the dog.
    Ross HM; Smelstoys JA; Davis GJ; Kapatkin AS; Del Piero F; Reineke E; Wang H; Zhu TC; Busch TM; Yodh AG; Hahn SM
    J Surg Res; 2006 Oct; 135(2):323-30. PubMed ID: 16650871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photodynamic therapy in the canine prostate using motexafin lutetium.
    Hsi RA; Kapatkin A; Strandberg J; Zhu T; Vulcan T; Solonenko M; Rodriguez C; Chang J; Saunders M; Mason N; Hahn S
    Clin Cancer Res; 2001 Mar; 7(3):651-60. PubMed ID: 11297261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen.
    Patel H; Mick R; Finlay J; Zhu TC; Rickter E; Cengel KA; Malkowicz SB; Hahn SM; Busch TM
    Clin Cancer Res; 2008 Aug; 14(15):4869-76. PubMed ID: 18676760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer.
    Du KL; Mick R; Busch TM; Zhu TC; Finlay JC; Yu G; Yodh AG; Malkowicz SB; Smith D; Whittington R; Stripp D; Hahn SM
    Lasers Surg Med; 2006 Jun; 38(5):427-34. PubMed ID: 16788929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy.
    Zhu TC; Dimofte A; Finlay JC; Stripp D; Busch T; Miles J; Whittington R; Malkowicz SB; Tochner Z; Glatstein E; Hahn SM
    Photochem Photobiol; 2005; 81(1):96-105. PubMed ID: 15535736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light.
    Yu G; Durduran T; Zhou C; Zhu TC; Finlay JC; Busch TM; Malkowicz SB; Hahn SM; Yodh AG
    Photochem Photobiol; 2006; 82(5):1279-84. PubMed ID: 16696593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimized interstitial PDT prostate treatment planning with the Cimmino feasibility algorithm.
    Altschuler MD; Zhu TC; Li J; Hahn SM
    Med Phys; 2005 Dec; 32(12):3524-36. PubMed ID: 16475751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy.
    Zhu TC; Finlay JC; Hahn SM
    J Photochem Photobiol B; 2005 Jun; 79(3):231-41. PubMed ID: 15896650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy.
    Finlay JC; Zhu TC; Dimofte A; Stripp D; Malkowicz SB; Busch TM; Hahn SM
    Photochem Photobiol; 2006; 82(5):1270-8. PubMed ID: 16808592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results.
    Kereiakes DJ; Szyniszewski AM; Wahr D; Herrmann HC; Simon DI; Rogers C; Kramer P; Shear W; Yeung AC; Shunk KA; Chou TM; Popma J; Fitzgerald P; Carroll TE; Forer D; Adelman DC
    Circulation; 2003 Sep; 108(11):1310-5. PubMed ID: 12939212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells.
    Chen Z; Woodburn KW; Shi C; Adelman DC; Rogers C; Simon DI
    Arterioscler Thromb Vasc Biol; 2001 May; 21(5):759-64. PubMed ID: 11348871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium.
    Chou TM; Woodburn KW; Cheong WF; Lacy SA; Sudhir K; Adelman DC; Wahr D
    Catheter Cardiovasc Interv; 2002 Nov; 57(3):387-94. PubMed ID: 12410519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer.
    Dimofte A; Zhu TC; Hahn SM; Lustig RA
    Lasers Surg Med; 2002; 31(5):305-12. PubMed ID: 12430147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study.
    Nathan TR; Whitelaw DE; Chang SC; Lees WR; Ripley PM; Payne H; Jones L; Parkinson MC; Emberton M; Gillams AR; Mundy AR; Bown SG
    J Urol; 2002 Oct; 168(4 Pt 1):1427-32. PubMed ID: 12352410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of motexafin lutetium-mediated intraperitoneal photodynamic therapy in a canine model.
    Griffin GM; Zhu T; Solonenko M; Del Piero F; Kapakin A; Busch TM; Yodh A; Polin G; Bauer T; Fraker D; Hahn SM
    Clin Cancer Res; 2001 Feb; 7(2):374-81. PubMed ID: 11234893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo optical properties of normal canine prostate at 732 nm using motexafin lutetium-mediated photodynamic therapy.
    Zhu TC; Hahn SM; Kapatkin AS; Dimofte A; Rodriguez CE; Vulcan TG; Glatstein E; Hsi RA
    Photochem Photobiol; 2003 Jan; 77(1):81-8. PubMed ID: 12856887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing damage to tumor blood vessels during motexafin lutetium-PDT through use of low fluence rate.
    Busch TM; Wang HW; Wileyto EP; Yu G; Bunte RM
    Radiat Res; 2010 Sep; 174(3):331-40. PubMed ID: 20726728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers.
    Chen Q; Huang Z; Luck D; Beckers J; Brun PH; Wilson BC; Scherz A; Salomon Y; Hetzel FW
    Photochem Photobiol; 2002 Oct; 76(4):438-45. PubMed ID: 12405153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo photodynamic therapy with the new near-IR absorbing water soluble photosensitizer lutetium texaphyrin and a high intensity pulsed light delivery system.
    Kostenich G; Orenstein A; Roitman L; Malik Z; Ehrenberg B
    J Photochem Photobiol B; 1997 May; 39(1):36-42. PubMed ID: 9210320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.